Cargando…
Determination of the Optimal Single Dose Treatment for Acoziborole, a Novel Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Study
BACKGROUND AND OBJECTIVES: Acoziborole is a novel boron-containing candidate developed as an oral drug for the treatment of human African trypanosomiasis (HAT). Results from preclinical studies allowed progression to Phase 1 trials. We aimed to determine the best dose regimen for all stages of HAT....
Autores principales: | Tarral, Antoine, Hovsepian, Lionel, Duvauchelle, Thierry, Donazzolo, Yves, Latreille, Mathilde, Felices, Mathieu, Gualano, Virginie, Delhomme, Sophie, Valverde Mordt, Olaf, Blesson, Severine, Voiriot, Pascal, Strub-Wourgaft, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042906/ https://www.ncbi.nlm.nih.gov/pubmed/36763327 http://dx.doi.org/10.1007/s40262-023-01216-8 |
Ejemplares similares
-
Determination of an Optimal Dosing Regimen for Fexinidazole, a Novel Oral Drug for the Treatment of Human African Trypanosomiasis: First-in-Human Studies
por: Tarral, Antoine, et al.
Publicado: (2014) -
Development and Introduction of Fexinidazole into the Global Human African Trypanosomiasis Program
por: Valverde Mordt, Olaf, et al.
Publicado: (2022) -
Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study
por: Ngay Lukusa, Ipos, et al.
Publicado: (2022) -
Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial
por: Betu Kumeso, Victor Kande, et al.
Publicado: (2023) -
Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial
por: Kande Betu Kumesu, Victor, et al.
Publicado: (2022)